ARWR
$56.33-0.63 (-1.11%)
Arrowhead Pharmaceuticals, Inc.
Recent News
Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies
SRPT plans FDA filings to convert Amondys 45 and Vyondys 53 to full approvals, leveraging new data despite a missed endpoint in its confirmatory study.
A Look At Arrowhead Pharmaceuticals (ARWR) Valuation As Recent Momentum Cools After A Strong Run
With no single headline event driving Arrowhead Pharmaceuticals (ARWR) today, recent trading and fundamentals still give you a few concrete markers to watch as you think about the stock. See our latest analysis for Arrowhead Pharmaceuticals. At a share price of US$56.96, Arrowhead’s 1-day and 7-day share price returns of 0.44% and 3.54% sit against a 30-day and 90-day share price pullback, while the 1-year total shareholder return is very large and well above the 3-year total shareholder...
Arrowhead Pharmaceuticals Inc. (ARWR): Billionaire Ken Fisher Bets Big on Pharma
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of Billionaire Ken Fisher’s 15 Most Notable Moves for 2026. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a relatively recent addition to the 13F portfolio of Fisher Asset Management. The fund first disclosed a stake in the firm in filings for the second quarter of 2024, comprising close to 12,000 shares […]
SRPT Stock Up as Enrollment Begins in DMD Gene Therapy Safety Study
Sarepta gains as enrollment begins in a new ENDEAVOR study cohort testing a sirolimus regimen to improve Elevidys safety in DMD patients.
Arrowhead (ARWR) FQ1 2026 Revenue Hits $264M as REDEMPLO Approval Marks Commercial Shift
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) is one of the best multibagger stocks to invest in according to billionaires. On February 5, Arrowhead Pharmaceuticals achieved a strategic turning point in FQ1 2026, transitioning into a commercial-stage organization following the US FDA approval of its first medicine, REDEMPLO (plozasiran). This siRNA therapeutic, designed to treat familial chylomicronemia syndrome/FCS, […]